Teva Pharmaceutical Industries Ltd (TEVA.TA)
23 May 2018
JERUSALEM Teva Pharmaceutical Industries said on Wednesday it could launch its migraine treatment as soon as mid-September, after an initial delay.
JERUSALEM, May 23 Teva Pharmaceutical Industries said on Wednesday it could launch its migraine treatment as soon as mid-September, after an initial delay.
JERUSALEM, May 23 Israeli drugmaker Teva Pharmaceutical Industries said on Wednesday it could launch its migraine treatment as early as mid-September, after an initial delay.
May 15 Warren Buffett's Berkshire Hathaway Inc on Tuesday said it has more than doubled its investment in generic drugmaker Teva Pharmaceutical Industries Ltd , and confirmed it has become Apple Inc's second-largest shareholder.
* TEVA CANADA ANNOUNCES THE LAUNCH OF TEVA-CYCLOSPORINE® OPHTHALMIC EMULSION, THE FIRST GENERIC VERSION OF RESTASIS® IN CANADA FOR THE TREATMENT OF DRY EYE DISEASE
* Teva's North American generic product sales down 23 pct (Adds comments from CEO interview, conference call, analyst quote)
* RESTRUCTURING PLAN ON-TRACK TO ACHIEVE $1.5 BILLION OF SAVINGS IN 2018 AND $3.0 BILLION BY END OF 2019
TEL AVIV, May 3 Israel's heavily indebted Teva Pharmaceutical Industries reported a smaller than-expected drop in first-quarter net profit on Thursday and raised its forecast for full-year earnings.
* Teva Pharmaceutical Industries said on Wednesday it had decided not to sell its SLE logistics centre in Israel.
* TEVA PRESENTS NEW LONG-TERM DATA DEMONSTRATING EFFICACY AND SAFETY OF COPAXONE (GLATIRAMER ACETATE INJECTION) 40 MG/ML